EVENT PREVIEW

Outsourcing in Clinical Trials Europe 2022

4-5 May 2022
Hyatt Regency Barcelona Tower
Barcelona, Spain
arena-international.com

Clinical trials are enormously complex and expensive undertakings. A clinical trial is a portion of the entire drug development process, from inception of the drug compound to bringing the drug to market. Globally, it is estimated that over US$40billion is spent on clinical trials each year.

A pharmaceutical company can expect to have spent $350m to get one drug to market, based on research conducted with 98 companies over a decade. On average, approximately 33% of the trial budget will be spent on investigative site (hospitals/universities etc) costs (reimbursement to investigators and site owners). Internal costs (resources deployed by the pharmaceutical company) may account for approximately 25% of the budget. The remainder is usually accounted for by outsourced services (central labs 5%, CROs – various, as high as 62% of trial budget in some cases).

Arena International are delighted to announce Outsourcing in Clinical Trials Europe will be returning to Barcelona for our in-person event.

For the 12th Annual event, our flagship European clinical show will provide delegates with practical take-aways and solutions to their most current operational and outsourcing challenges in clinical trials. This is an event not to be missed!

The 2022 program boasts multiple streams across 2 days, jam packed with content. Day 1 will kick off with a low down on Decentralized and Hybrid Trials, looking at the best way to implement these in Europe, by the Head of LEO Innovation Lab. We will also hear a keynote on ‘The Diversity Conversation’, discussing underrepresentation in clinical trials and what we can do about it now.

The Technology track will see Kai Langel, Senior Director of Strategy and Innovation at Janssen, discuss digital therapeutics; as well as an interactive discussion on how to create a clinical landscape where small companies have better access to technology.

Opening Day 2 we have our expert panel debating how best to build trust with your CRO in a virtual landscape. The Speaking Faculty includes the likes of Janssen, Sanofi, Fresenius Medical Care,Alexion, AstraZeneca, Daiichi Sankyo, Roche, Medac and many more.

Go to article: Home | Tackling insulin prices Go to article: In this issueGo to article: CSafe GlobalGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Molnar-Institute Company Insight Go to article: Molnar-InstituteGo to article: CommentGo to article: Why did the cannabis industry blossom during the pandemic?Go to article: Negative AdCom vote for Amylyx’s ALS drug AMX0035, but hope remainsGo to article: Will Russia’s invasion affect biopharmaceutical licensing agreements?Go to article: Fall from grace? What 2022 may have in stock for biopharmaceutical SPACsGo to article: BEA TechnologiesGo to article: In DepthGo to article: Insulin pricing: could an e-commerce approach cut costs?Go to article: Bacteria and balance: how understanding the vaginal microbiome can help discover new drugs Go to article: Big pharma’s gradual retreat on clinical trials in Russia Go to article: Covid-19, flu combo vaccines an advance but with rollout quandariesGo to article: FDA shows unease about marketing approval applications based on single-country tGo to article: In DataGo to article: How big is the gender pay gap in the pharma industry in Britain?Go to article: Where is trade most likely to be disrupted in pharma from the Russian invasion oGo to article: Big data innovation among pharma companies dropped off in the last quarterGo to article: Event: Outsourcing in Clinical Trials Europe 2022Go to article: EventsGo to article: Next issue